NAD+ and Lupus: NR Trials, Skin Studies and Evidence Limits

NAD+ is not an established lupus treatment, but disease-specific research does exist. Oral nicotinamide riboside (NR) is under investigation at NIH, and niacinamide has separate research in lupus-related skin disease. These are different interventions and different questions; neither establishes that an NAD+ infusion controls systemic lupus ¹²³.

Start with the differences between NAD+, NR and NMN. Our NAD+ therapy evidence guide explains why a biological hypothesis and a demonstrated treatment result deserve different weight.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

RxSpan MD

Physician-led NAD+ & longevity telehealth

See RxSpan MD↗

Why lupus researchers are interested in NR

Lupus is an autoimmune disease that can affect multiple organs. That makes a generic promise to “boost immunity” an inadequate explanation of what a product would do. The relevant goal is controlling harmful disease activity while preserving useful immune function ⁴.

A 2022 study examined NR-related changes in immune cells. It included work in healthy volunteers and experiments on monocytes collected from people with systemic lupus erythematosus (SLE). In the lupus-cell experiments, NR reduced autophagy and release of interferon-beta, a type I interferon involved in immune signaling ¹.

The distinction is crucial: treating cells taken from a patient is not the same as treating that patient's lupus. The paper supports a reason to investigate NR, rather than proving fewer flares, less organ damage or a safe replacement for prescribed therapy. An immune marker can help researchers test a mechanism without answering those clinical questions.

What the NIH lupus study is testing

The official record for NCT06032923 describes randomized, double-blind comparison of NR and placebo, with healthy controls also included in the overall enrollment plan. Its primary question concerns type I interferon signaling and cytokine release in monocytes ². NIH's participant information describes a 12-week intervention for participants with SLE; healthy controls provide comparison blood samples without taking the supplement ⁵.

When checked on October 15, 2026, the registry listed recruiting and had no posted results. Its latest update was posted July 31, 2026, and completion was estimated for August 2028. Dates are plans, not promised publication dates ².

Eligibility also limits interpretation. The SLE group consists of adult women with mild or moderate activity. Active kidney or central nervous system disease and major renal or liver dysfunction are exclusions. Recent use of certain biologic or other intensive therapies is also restricted ².

Even a future positive finding would therefore need careful interpretation before being applied to severe lupus, lupus nephritis or a different medication combination. For the organ-specific evidence questions, see our NAD precursors and kidney-health guide.

What about niacinamide for lupus skin lesions?

A separate 2023 pilot studied topical niacinamide in 60 people with discoid lupus, a form of cutaneous lupus. It compared two concentrations with a vehicle placebo over 12 weeks. The authors reported improvement in skin lesions, with more irritation at the higher concentration, and called for larger studies with longer follow-up ³.

This is a small dermatology study of a locally applied preparation. It does not show that oral NR, NMN or injected NAD+ treats systemic disease. Nor should a skin result be described as evidence of protection against kidney or cardiovascular complications. A dermatologist can assess whether this narrow research question is relevant to a person's lesions and current treatment.

There is also a registered oral nicotinamide study for lupus-associated skin lesions, NCT03260166. It is uncontrolled and open-label. Its record had no posted results and an unknown status, with its last update posted in February 2021 ⁶. A registration is evidence that a question was planned for study; it is not evidence of success.

Does this support an NAD+ injection program?

The sources above do not establish that commercial NAD+ shots or infusions improve lupus outcomes. The molecule, route and intended outcome must match the claim. Our NAD+ injection review explains the available route-specific evidence.

A clinic should be able to identify the exact study supporting the benefit it advertises. If it cites the monocyte experiment, ask whether the finding was measured in isolated cells or in treated patients. If it cites the topical pilot, ask why a skin preparation would establish benefit from an injection. These questions keep a real research signal from becoming a broader promise than the experiment can support.

Keep lupus care coordinated

NIAMS describes treatment goals that include reducing activity, preventing flares and limiting organ damage. Treatment depends on the organs involved and may require several medicines. It advises discussing complementary products with the treating team and continuing prescribed care unless a clinician recommends a change ⁴.

Bring the complete product label to the rheumatologist or pharmacist, including additional vitamins or ingredients. Ask whether evidence includes people using your medicines and with your pattern of lupus. Missing interaction information is not confirmation that a combination is safe; the NMN interaction guide explains that broader problem.

The current research is specific and worth following. Its value comes from testing defined hypotheses, not from treating all NAD-related products as a proven lupus therapy.